The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic in...

Full description

Bibliographic Details
Main Authors: Juan P. Palavicini, Alberto Chavez-Velazquez, Marcel Fourcaudot, Devjit Tripathy, Meixia Pan, Luke Norton, Ralph A. DeFronzo, Christopher E. Shannon
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Physiology
Subjects:
adipose
obesity
lipidomics
pioglitazone
type 2 diabetes
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2021.784391/full

Internet

https://www.frontiersin.org/articles/10.3389/fphys.2021.784391/full

Similar Items